Sanofi Pasteur’s Investigational H5N1 Influenza Vaccine Achieves High Immune Response At Low Dosage

Sanofi pasteur, the vaccines division of sanofi-aventis Group, announced data showing that its new investigational H5N1 pandemic influenza vaccine containing a proprietary adjuvant achieved a high immune response at the lowest dose of H5N1 antigen reported to date. The vaccine containing only 1. [click link for full article]

More: continued here

Filed under: Bird Flu on September 21st, 2007